The addition of hydroxychloroquine (HCQ) to methotrexate (MTX) therapy for rheumatoid arthritis increases a patient’s exposure to the methotrexate, which investigators in Australia believe may explain the heightened efficacy of the drug combination compared with methotrexate alone.
However, this increased potency may also heighten the risk for renal toxicity, since methotrexate is almost entirely eliminated by the kidneys, they note.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!